These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8106066)

  • 41. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Schaefer UW
    Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse.
    Ustün C; Arslan O; Beksaç M; Koç H; Gürman G; Ozçelik T; Yilmaz B; Ilhan O; Akan H; Ozcan M; Demirer T; Uysal A; Konuk N; Arat M; Dilek I; Celebi H; Coskun HS
    Biol Blood Marrow Transplant; 1999; 5(1):28-35. PubMed ID: 10232738
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peripheral blood progenitor cells: a replacement for marrow transplantation?
    Champlin RE
    Semin Oncol; 1996 Apr; 23(2 Suppl 4):15-21. PubMed ID: 8600543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.
    Bensinger WI; Martin PJ; Storer B; Clift R; Forman SJ; Negrin R; Kashyap A; Flowers ME; Lilleby K; Chauncey TR; Storb R; Appelbaum FR
    N Engl J Med; 2001 Jan; 344(3):175-81. PubMed ID: 11172139
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Collection of hematopoietic progenitor cells from healthy donors].
    Bojanić I; Cepulić BG; Mazić S
    Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
    Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
    Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Allogeneic bone marrow transplantation in myeloid leukemia: chemical conditioning, clinical course and results].
    Glejzer O; Sedzimirska M; Tomaszewska-Toporska B; Tomeczko J; Kołodziej J; Pacuszko T; Was A; Bocheńska J; Jaźwiec B; Klimczak A
    Acta Haematol Pol; 1992; 23(2 Suppl 1):49-59. PubMed ID: 1488872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow.
    Elfenbein GJ; Sackstein R
    Exp Hematol; 2004 Apr; 32(4):327-39. PubMed ID: 15050742
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone marrow processing for transplantation.
    Areman EM; Sacher RA
    Transfus Med Rev; 1991 Jul; 5(3):214-27. PubMed ID: 1687956
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors influencing reconstitution by bone marrow transplantation.
    van Bekkum DW; Wielenga JJ; van Gils F; Wagemaker G
    Prog Clin Biol Res; 1990; 352():479-91. PubMed ID: 1698302
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment.
    Shpall EJ; Jones RB; Bearman SI; Franklin WA; Archer PG; Curiel T; Bitter M; Claman HN; Stemmer SM; Purdy M
    J Clin Oncol; 1994 Jan; 12(1):28-36. PubMed ID: 7505806
    [TBL] [Abstract][Full Text] [Related]  

  • 55. rhGM-CSF after allogeneic bone marrow transplantation from unrelated donors: a pilot study of cyclosporine and prednisone as graft-versus-host disease prophylaxis.
    Nemunaitis J; Anasetti C; Bianco JA; Hasen J; Singer JW
    Leuk Lymphoma; 1993 Jun; 10(3):177-81. PubMed ID: 8220115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk assessment in haematopoietic stem cell transplantation: stem cell source.
    Urbano-Ispizua A
    Best Pract Res Clin Haematol; 2007 Jun; 20(2):265-80. PubMed ID: 17448961
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of ultraviolet-B irradiation on engraftment, graft-versus-host disease and graft-versus-leukemia effect in a rat model for allogeneic bone marrow transplantation.
    Gowing H; Braakman E; Hagenbeek A; Lawler M; McCann SR; Pamphilon DH; Martens AC
    Bone Marrow Transplant; 1998 Apr; 21(8):801-7. PubMed ID: 9603404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
    de Lima M; van Besien K; Gajewski J; Khouri I; Andersson B; Korbling M; Champlin R; Giralt S
    Bone Marrow Transplant; 2000 Aug; 26(3):333-8. PubMed ID: 10967575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality.
    Robin M; Guardiola P; Dombret H; Baruchel A; Esperou H; Ribaud P; Devergie A; Gluckman E; Socié G
    Bone Marrow Transplant; 2003 May; 31(10):877-87. PubMed ID: 12748664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.